Related Articles
Oncotype DX 21‑gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21‑gene recurrence score of 26‑30
Individualized chemotherapy guided by the expression of <em>ERCC1, RRM1, TUBB3, TYMS</em> and <em>TOP2A</em> genes versus classic chemotherapy in the treatment of breast cancer: A comparative effectiveness study
Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways